GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Ocean Biomedical Inc (NAS:OCEA) » Definitions » Altman Z-Score

Ocean Biomedical (Ocean Biomedical) Altman Z-Score : N/A (As of Jun. 11, 2024)


View and export this data going back to 2023. Start your Free Trial

What is Ocean Biomedical Altman Z-Score?

The Altman Z-Score is a model designed to predict the likelihood of a company going bankrupt within the next two years. Created by American finance professor Edward Altman in 1968, the model is specifically designed for publicly traded manufacturing companies with assets greater than $1 million.

Ocean Biomedical has a Altman Z-Score of N/A, indicating it is in Distress Zones. This implies bankrupcy possibility in the next two years.

The zones of discrimination were as such:

When Altman Z-Score <= 1.8, it is in Distress Zones.
When Altman Z-Score >= 3, it is in Safe Zones.
When Altman Z-Score is between 1.8 and 3, it is in Grey Zones.

The historical rank and industry rank for Ocean Biomedical's Altman Z-Score or its related term are showing as below:


Ocean Biomedical Altman Z-Score Historical Data

The historical data trend for Ocean Biomedical's Altman Z-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Ocean Biomedical Altman Z-Score Chart

Ocean Biomedical Annual Data
Trend Dec19 Dec20 Dec21 Dec22
Altman Z-Score
- - - -

Ocean Biomedical Quarterly Data
Dec19 Mar20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23
Altman Z-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Ocean Biomedical's Altman Z-Score

For the Biotechnology subindustry, Ocean Biomedical's Altman Z-Score, along with its competitors' market caps and Altman Z-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Ocean Biomedical's Altman Z-Score Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Ocean Biomedical's Altman Z-Score distribution charts can be found below:

* The bar in red indicates where Ocean Biomedical's Altman Z-Score falls into.



Ocean Biomedical Altman Z-Score Calculation

Altman Z-Score model is an accurate forecaster of failure up to two years prior to distress. It can be considered the assessment of the distress of industrial corporations.

Ocean Biomedical's Altman Z-Score for today is calculated with this formula:

Z=1.2*X1+1.4*X2+3.3*X3+0.6*X4+1.0*X5
=1.2*-28.9234+1.4*-173.8109+3.3*-78.6178+0.6*0.6839+1.0*0
=N/A

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency. GuruFocus does not calculate Altman Z-Score when X4 or X5 value is 0.

Trailing Twelve Months (TTM) ended in Sep. 2023:
Total Assets was $1.03 Mil.
Total Current Assets was $1.03 Mil.
Total Current Liabilities was $30.85 Mil.
Retained Earnings was $-179.20 Mil.
Pre-Tax Income was -14.087 + -11.431 + -72.092 + 15.418 = $-82.19 Mil.
Interest Expense was -0.293 + -0.668 + -0.301 + 0.125 = $-1.14 Mil.
Revenue was 0 + 0 + 0 + 0 = $0.00 Mil.
Market Cap (Today) was $52.15 Mil.
Total Liabilities was $76.26 Mil.

* Note that for stock reported semi-annually or annually, GuruFocus uses latest annual data as the TTM data.

X1=Working Capital/Total Assets
=(Total Current Assets - Total Current Liabilities)/Total Assets
=(1.031 - 30.851)/1.031
=-28.9234

X2=Retained Earnings/Total Assets
=-179.199/1.031
=-173.8109

X3=Earnings Before Interest and Taxes/Total Assets
=(Pre-Tax Income - Interest Expense)/Total Assets
=(-82.192 - -1.137)/1.031
=-78.6178

X4=Market Value Equity/Book Value of Total Liabilities
=Market Cap/Total Liabilities
=52.149/76.255
=0.6839

X5=Revenue/Total Assets
=0/1.031
=0

The zones of discrimination were as such:

Distress Zones - 1.81 < Grey Zones < 2.99 - Safe Zones

Ocean Biomedical has a Altman Z-Score of N/A indicating it is in Distress Zones.

Study by Altman found that companies that are in Distress Zone have more than 80% of chances of bankruptcy in two years.


Ocean Biomedical  (NAS:OCEA) Altman Z-Score Explanation

X1: The Working Capital/Total Assets (WC/TA) ratio is a measure of the net liquid assets of the firm relative to the total capitalization. Working capital is defined as the difference between current assets and current liabilities. Ordinarily, a firm experiencing consistent operating losses will have shrinking current assets in relation to total assets. Altman found this one proved to be the most valuable liquidity ratio comparing with the current ratio and the quick ratio. This is however the least significant of the five factors.

X2: Retained Earnings/Total Assets: the RE/TA ratio measures the leverage of a firm. Retained earnings is the account which reports the total amount of reinvested earnings and/or losses of a firm over its entire life. Those firms with high RE, relative to TA, have financed their assets through retention of profits and have not utilized as much debt.

X3, Earnings Before Interest and Taxes/Total Assets (EBIT/TA): This ratio is a measure of the true productivity of the firm's assets, independent of any tax or leverage factors. Since a firm's ultimate existence is based on the earning power of its assets, this ratio appears to be particularly appropriate for studies dealing with corporate failure. This ratio continually outperforms other profitability measures, including cash flow.

X4, Market Value of Equity/Book Value of Total Liabilities (MVE/TL): The measure shows how much the firm's assets can decline in value (measured by market value of equity plus debt) before the liabilities exceed the assets and the firm becomes insolvent.

X5, Revenue/Total Assets (S/TA): The capital-turnover ratio is a standard financial ratio illustrating the sales generating ability of the firm's assets.

Read more about Altman Z-Score and the original research.


Be Aware

Altman Z-Score does not apply to financial companies.


Ocean Biomedical Altman Z-Score Related Terms

Thank you for viewing the detailed overview of Ocean Biomedical's Altman Z-Score provided by GuruFocus.com. Please click on the following links to see related term pages.


Ocean Biomedical (Ocean Biomedical) Business Description

Traded in Other Exchanges
Address
55 Claverick Street, Room 325, Providence, RI, USA, 02903
Ocean Biomedical Inc is a biopharmaceutical company. It is dedicated towards partnering with inventor-scientists and research institutes to bridge the gap between basic research and clinical development, to get new medicines to the patients who need it most.
Executives
Robert J Sweeney officer: Chief Accounting Officer 20298 CRAIGEN CIRCLE, SARATOGA CA 95070
M Michelle Berrey director 303A COLLEGE ROAD EAST, PRINCETON NJ 08450
William F Owens director C/O KEY ENERGY SERVICES, INC., 1301 MCKINNEY STREET, SUITE 1800, HOUSTON TX 77010
Inderjote S Kathuria officer: Chief Strategy Officer 19W060 AVENUE LATOUR, OAK BROOK IL 60523
Gurinder S Kalra officer: Chief Financial Officer 2305 WASHINGTON STREET, APT 301, SAN FRANCISCO CA 94115
Chirinjeev Kathuria director C/O UPHEALTH HOLDINGS, INC., 14000 S. MILITARY TRAIL #203, DELRAY BEACH FL 33484
Jerome Ringo director 1731 EMBARCADERO ROAD SUITE 200, PALO ALTO CA 94303
Poseidon Bio, Llc 10 percent owner OCEAN BIOMEDICAL, INC., 55 CLAVERICK ST., ROOM 325, PROVIDENCE RI 02903
Daniel Behr officer: EVP, Innov./Acad. P'ships Head OCEAN BIOMEDICAL, INC., 55 CLAVERICK ST., ROOM 325, PROVIDENCE RI 02903
Jack A Elias director OCEAN BIOMEDICAL, INC., 55 CLAVERICK ST., ROOM 325, PROVIDENCE RI 02903
Jonathan Kurtis director OCEAN BIOMEDICAL, INC., 55 CLAVERICK ST., ROOM 325, PROVIDENCE RI 02903
Elizabeth Ng director, officer: Chief Executive Officer OCEAN BIOMEDICAL, INC., 55 CLAVERICK ST., ROOM 325, PROVIDENCE RI 02903
Martin D Angle director OCEAN BIOMEDICAL, INC., 55 CLAVERICK ST., ROOM 325, PROVIDENCE RI 02903
Aesther Healthcare Sponsor, Llc 10 percent owner 515 MADISON AVE., SUITE 8078, NEW YORK NY 10022
Michael L Peterson director 17 CANARY COURT, DANVILLE CA 94526

Ocean Biomedical (Ocean Biomedical) Headlines

From GuruFocus